Healthpluser

Spread the love

<figure class="img_container" style="float:left;margin-right:10px;width:350px;;margin-bottom:5px;max-width:100%;"><img width="590" height="442" class="unveil" loading="eager" style="width:100%;max-height:100%" src="https://img.etb2bimg.com/files/cp/upload-1716881542-ethealthworld.webp" data-src="https://etimg.etb2bimg.com/photo/117452055.cms" captionrendered="1" alt=""><figcaption class="caption"></figcaption></figure>Gdansk: Polish medical diagnostics company Diagnostyka has set a maximum price for shares offered in its <a id="19913114" type="General" weightage="20" keywordseo="initial-public-offering" source="keywords" class="news-keywords" href="/tag/initial+public+offering">initial public offering</a> (IPO) at 105 zlotys, valuing the offering at up to 1.7 billion zlotys ($416.1 million), it said in a prospectus late on Tuesday. At a maximum price, Diagnostyka is valued at up to 3.54 billion zlotys. A bookrunner said the price range for the offering was between 95 zlotys and 105 zlotys. <!– PROMOSLOT_M –> Its shareholder LX Beta S.a r.l., backed by <a id="25101372" type="General" weightage="20" keywordseo="private-equity-fund-Mid-Europa-Partners" source="keywords" class="news-keywords" href="/tag/private+equity+fund+mid+europa+partners">private equity fund Mid Europa Partners</a>, will offer around 16 million shares, or a 47.83per cent stake in the company. Diagnostyka, which performs blood, microbiological and genetic tests as well as diagnostic imaging, will not get any money from the IPO. <!– PROMOSLOT –> The offering will test the waters for deals in Warsaw after Zabka’s 6.45 billion zloty share sale in October, the largest IPO in Poland since that of e-commerce platform Allegro in 2020. <!– PROMOSLOT_M –> Zabka’s shares are up 23per cent so far this year, after trading mostly below its 21.5 zloty IPO price in the months since the debut. The final price for Diagnostyka’s offer is expected to be announced on or around Jan. 30, while the shares are set to make their stock market debut on Feb. 7. Diagnostyka, founded in 1998, has said it is a market leader in Poland’s medical diagnostics industry with more than 1,100 blood collection points, 156 laboratories and 19 imaging facilities. <!– PROMOSLOT_M –><!– PROMOSLOT –> The group competes in laboratory testing with Synevo, owned by Sweden’s Medicover and Grupa Alab, and in diagnostic imaging with Voxel and insurer PZU . It reported revenue of 1.6 billion zlotys and a recurring core profit (EBITDA) of 383 million zlotys in 2023. It said in the prospectus that the management intends to recommend a dividend of 50per cent of net profit, with possibility to hike that in years of "exceptionally good" financial results. ($1 = 4.0857 zlotys) (Reporting by Adrianna Ebert and Anna Pruchnicka; Editing by Milla Nissi) </body>","next_sibling":[{"msid":117426395,"title":"AOI Nagpur introduces Advanced Gallium PET CT scans for cancer detection","entity_type":"ARTICLE","link":"/news/diagnostics/aoi-nagpur-introduces-advanced-gallium-pet-ct-scans-for-cancer-detection/117426395","link_next_mobile":"/news/diagnostics/aoi-nagpur-introduces-advanced-gallium-pet-ct-scans-for-cancer-detection/117426395?next=1","category_name":null,"category_name_seo":"diagnostics"}],"related_content":[],"seoschemas":false,"social_share":{"fb":"/information/diagnostics/polands-diagnostyka-sets-maximum-price-in-ipo-at-105-zlotys/shr/117449331?utm_source=fb&utm_medium={{DEVICE_TYPE}}","x":"/information/diagnostics/polands-diagnostyka-sets-maximum-price-in-ipo-at-105-zlotys/shr/117449331?utm_source=twitter&utm_medium={{DEVICE_TYPE}}","whatsapp":"/information/diagnostics/polands-diagnostyka-sets-maximum-price-in-ipo-at-105-zlotys/shr/117449331?utm_source=wapp&utm_medium={{DEVICE_TYPE}}","linkdin":"/information/diagnostics/polands-diagnostyka-sets-maximum-price-in-ipo-at-105-zlotys/shr/117449331?utm_source=linkedin&utm_medium={{DEVICE_TYPE}}","telegram":"/information/diagnostics/polands-diagnostyka-sets-maximum-price-in-ipo-at-105-zlotys/shr/117449331?utm_source=telegram&utm_medium={{DEVICE_TYPE}}","copy":"/information/diagnostics/polands-diagnostyka-sets-maximum-price-in-ipo-at-105-zlotys/shr/117449331?utm_source=copy&utm_medium={{DEVICE_TYPE}}"},"cat_msid":44909138,"cat_sub_msid":false,"msid":117449331,"entity_type":"ARTICLE","title":"Poland’s Diagnostyka units most value in IPO at 105 zlotys/shr","synopsis":"Diagnostyka, which performs blood, microbiological and genetic exams in addition to diagnostic imaging, is not going to get any cash from the IPO.","titleseo":"diagnostics/polands-diagnostyka-sets-maximum-price-in-ipo-at-105-zlotys/shr","standing":"ACTIVE","authors":[],"Alttitle":{"minfo":""},"next_promo_stories":[{"id":"117674599","type":"next_article"}],"artag":"Reuters","artdate":"2025-01-22 13:04:00","lastupd":"2025-01-22 14:38:11","breadcrumbTags":["Diagnostyka IPO","initial public offering","medical diagnostics industry Poland","Diagnostyka share price","Zabka IPO","private equity fund Mid Europa Partners"],"secinfo":{"seolocation":"diagnostics/polands-diagnostyka-sets-maximum-price-in-ipo-at-105-zlotys/shr"}}” data-type=”information” id=”news_dtl_117449331″ page-title=”Poland’s Diagnostyka units most value in IPO at 105 zlotys/shr”>

Diagnostyka, which performs blood, microbiological and genetic exams in addition to diagnostic imaging, is not going to get any cash from the IPO.

Reuters

Up to date On Jan 22, 2025 at 02:38 PM IST

Gdansk: Polish medical diagnostics firm Diagnostyka has set a most value for shares supplied in its <a id=” captionrendered=”1″ data-src=”https://etimg.etb2bimg.com/photograph/117452055.cms” top=”442″ href=”/tag/preliminary+public+providing” keywordseo=”initial-public-offering” loading=”keen” supply=”key phrases” src=”https://img.etb2bimg.com/recordsdata/cp/upload-1716881542-ethealthworld.webp” kind=”Basic” weightage=”20″ width=”590″>preliminary public providing (IPO) at 105 zlotys, valuing the providing at as much as 1.7 billion zlotys ($416.1 million), it stated in a prospectus late on Tuesday.

At a most value, Diagnostyka is valued at as much as 3.54 billion zlotys.

A bookrunner stated the worth vary for the providing was between 95 zlotys and 105 zlotys.

Its shareholder LX Beta S.a r.l., backed by private equity fund Mid Europa Partners, will supply round 16 million shares, or a 47.83per cent stake within the firm.

Diagnostyka, which performs blood, microbiological and genetic exams in addition to diagnostic imaging, is not going to get any cash from the IPO.

The providing will take a look at the waters for offers in Warsaw after Zabka’s 6.45 billion zloty share sale in October, the most important IPO in Poland since that of e-commerce platform Allegro in 2020.

Zabka’s shares are up 23per cent to date this yr, after buying and selling principally beneath its 21.5 zloty IPO value within the months because the debut.

The ultimate value for Diagnostyka’s supply is anticipated to be introduced on or round Jan. 30, whereas the shares are set to make their inventory market debut on Feb. 7.

Diagnostyka, based in 1998, has stated it’s a market chief in Poland’s medical diagnostics trade with greater than 1,100 blood assortment factors, 156 laboratories and 19 imaging services.

The group competes in laboratory testing with Synevo, owned by Sweden’s Medicover and Grupa Alab, and in diagnostic imaging with Voxel and insurer PZU .

It reported income of 1.6 billion zlotys and a recurring core revenue (EBITDA) of 383 million zlotys in 2023.

It stated within the prospectus that the administration intends to suggest a dividend of 50per cent of web revenue, with chance to hike that in years of “exceptionally good” monetary outcomes. ($1 = 4.0857 zlotys) (Reporting by Adrianna Ebert and Anna Pruchnicka; Modifying by Milla Nissi)